A prospective verification study demonstrates that the Preecludia™ test has high sensitivity and high negative predictive value.
Preeclampsia complicates 2 – 8% of all pregnancies worldwide and is one of the leading causes of maternal and neonatal mortality.1 There is no definitive, diagnostic test for preeclampsia. Current tools, such as blood pressure readings and urine protein tests, measure the maternal clinical response of preeclampsia but are not directly linked to the underlying pathophysiology of the syndrome. Accurately assessing a low risk of developing preterm preeclampsia could potentially avoid unnecessary interventions and premature delivery.
The goal of this observational clinical verification study was to determine the performance of the Preecludia™ test to assess the risk for preeclampsia within 14 days of sample collection from women presenting with signs or symptoms of possible preeclampsia.2